Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer
Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer
复制标题
DOI：
10.1016/j.prp.2014.09.010
复制
发表时间：
2015-01-01
影响因子：
2.8
通讯作者：
Ye, Qing
中科院分区：
文献类型：
--
作者：
Pu, Xiaohong;Shi, Jiong;Ye, Qing
已证实17号染色体着丝粒（CEP17）扩增导致误导人表皮生长因子受体2（HER2）基因荧光原位杂交（FISH）结果，从而妨碍了一些乳腺癌患者基于抗HER2的治疗。我们使用2013年美国临床肿瘤学会/美国病理学家学会（ASCO/CAP）评分标准评估175例17号染色体多体性乳腺癌患者的HER2扩增状态。我们使用免疫组织化学（IHC）来确定HER2扩增状态，并使用双色FISH来检测CEP17，并使用2007年ASCO/CAP标准审查了初步评估结果。在175例病例中，分别有17例、95例和63例为IHC 0/1+、2+和3+。与使用2007年标准评估的病例相比，根据2013年ASCO/CAP标准评估的IHC HER2状态识别出显著更多的HER2阳性病例（p <0.05）。当FISH结果与2013年标准平行评估时，我们发现22例病例不是HER2阴性，尽管存在多体性17，根据2013年标准，这表明HER2阳性状态。我们的研究结果表明，在乳腺癌中，HER2状态在多体性17的存在下可能会有所不同的评分标准。反过来，使用2013年ASCO/CAP标准进行FISH和评估样本意味着更多的乳腺癌患者可能适合曲妥珠单抗的靶向治疗，可能会改善其结果。(C)2014作者由Elsevier GmbH出版。
It has been proven that chromosome 17 centromere (CEP17) amplification causes misleading human epidermal growth factor receptor 2 (HER2) gene fluorescence in situ hybridization (FISH) results, precluding anti-HER2-based therapy in some patients with breast carcinoma. We used the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) scoring criteria to evaluate HER2 amplification status in 175 cases of breast carcinoma with chromosome 17 polysomy. We used immunohistochemistry (IHC) to determine the HER2 amplification status, and 2-color FISH to detect CEP17, and reviewed the results of initial evaluation using the 2007 ASCO/CAP criteria. Of the 175 cases, 17, 95, and 63 were IHC 0/1+, 2+, and 3+, respectively. Evaluation of IHC HER2 status according to the 2013 ASCO/CAP criteria identified significantly more HER2-positive cases compared to cases evaluated using the 2007 criteria (p < 0.05). When the FISH results were evaluated in parallel with the 2013 criteria, we found that 22 cases were not HER2-negative despite the presence of polysomy 17, which, according to the 2013 criteria, indicates HER2-positive status. Our findings indicate that in breast carcinoma, HER2 status in the presence of polysomy 17 may vary with the scoring criteria used. In turn, performing FISH and evaluating samples using the 2013 ASCO/CAP criteria means that more patients with breast cancer may be appropriate for targeted treatment with trastuzumab, potentially improving their outcome. (C) 2014 The Authors. Published by Elsevier GmbH.